Successful treatment of thrombocytopenia, anasarca, fever, reticulin myelofibrosis/renal insufficiency, and organomegaly syndrome using plasma exchange followed by rituximab in the intensive care unit

Thrombocytopenia, anasarca, fever, reticulin myelofibrosis/renal insufficiency, and organomegaly (TAFRO) syndrome is treated using corticosteroids and/or immunosuppressive agents as first-line therapy. We report the case of a 69-year-old female with TAFRO syndrome in which the patient presented multiple organ failure and steroid resistance, which was successfully treated using plasma exchange (PE) followed by rituximab.